An International Publications House

Albert Science International Organization

Connecting People With Pioneering Thought

Albert Science International Organization (ASIO) is international , peer-reviewed , open access , cum print version & online journals.
Articles
Current
Archive
Special
Editorial Board
Paper In Publication Desk
Author Instruction
Author Desk
Call for Paper
Upcoming Journals and Books
Indexing of ASIO Journals
Author Instructions for Manuscript
Model Manuscript
Covering Letter
Publication Charges
Our Journals
ASIO Journal of Engineering & Technological Perspective Research (ASIO-JETPR) [ISSN: 2455-3794]
ASIO Journal of Medical & Health Sciences Research (ASIO-JMHSR)
ASIO Journal of Nursing & Physiotherapeutic Research (ASIO-JNPR)
ASIO Journal of Pharmaceutical & Herbal Medicines Research (ASIO-JPHMR) [ISSN: 2455-281X]
ASIO Journal of Microbiology, Food Science & Biotechnological Innovations (ASIO-JMFSBI) [ISSN: 2455-3751]
ASIO Journal of Chemistry, Physics, Mathematics & Applied Sciences (ASIO-JCPMAS) [ISSN: 2455-7064 ]
ASIO Journal of Humanities, Management & Social Sciences Invention (ASIO-JHMSSI) [ISSN: 2455-2224]
ASIO Journal of Analytical Chemistry (ASIO-JAC) [ISSN: 2455-7072]
ASIO Journal of Drug Delivery (ASIO-JDD) [ISSN: 2455-2828]
ASIO Journal of Experimental Pharmacology & Clinical Research (ASIO-JEPCR) [ISSN: 2455-7080]
ASIO Publication of Thesis & Dissertation (ASIO-PTD)
Health & Medicine Blog (ASIO)
JOURNALS || ASIO Journal of Drug Delivery (ASIO-JDD) [ISSN: 2455-2828]
PHARMACEUTICAL APPLICATIONS OF LIQUID CRYSTAL WITH SPECIAL EMPHASIZED ON ADVANCED DRUG DELIVERY SYSTEM: AN OVERVIEW

Author Names : Shiwangi Periwal
Page No. : 01-10
Read Hit : 1048
Pdf Downloads Hit : 21  Volume 4 Issue 1
Article Overview

ARTICLE DESCRIPTION: 

Shiwangi Periwal , Shubhangi Gupta , Bankim Chandra Nandy, Beduin Mahanti, Pharmaceutical applications of liquid crystal with special emphasized on advanced drug delivery system: an overview, ASIO Journal of Drug Delivery (ASIO-JDD), 4(1), 01-10. 

ARTICLE TYPE: REVIEW

DOI Link:: http://doi-ds.org/doilink/10.2016-21915953/ ; DOI Link :: http://doi-ds.org/doilink/06.2020-24855393/

 


ABSTRACT:

Liquid crystals are substances that flow like liquid but maintain some of the ordered structure characteristic of crystalline solid. Liquid crystal can be divided into thermotropic and lyotropic phase. The thermotropic is generated by temperature variation in the liquid state, whereas lyotropic is formed by dissolving the compound in certain solvents. The liquid crystal systems have some advantages such as drug solubilization level, drug degradation, biological and chemical sensing, stability of drug, control drug release, light, thin, sustained and controlled release pharmaceutical properties. Liquid crystal technology has had a major effect in many areas of science pharmacy and engineering, as well as device technology. The drug delivery to site of target can be achieved by using liquid crystal systems. Objective of this review is to provide information in development of targeted drug delivery system, depth information of pharmaceutical liquid crystal technology, its classification and application in the pharmaceutical field.

Keywords: Liquid crystalline system, history, display, classification, patent with liquid crystal application.

Reference
  1. Yogeshvar Tyagi, liquid crystal: An approach to different states of Matter, Pharma innovation journal, 2018, 7(5): 540-545.
  2. Ashish P. Lodha, Gauri P. Jadhav, Vishal V. Pande, Liquid crystals as a Cubo-Hexagonal Topical Controlled Drug delivery system, Pharmacophore, 2014, 5 (3): 430-441.
  3. Pallavi Kawara, Vishal Pande, Liquid Crystals: A Novel Approach Drug Delivery System, JETIR June , 2019, Volume-6,402-410.
  4. Gennes, P.G. and Prost, J. The Physics of Liquid Crystals, Claredon Press ,1993,4(3),7.
  5. Shaikh Zeba, Liquid Crystalline System: A Novel approach for Drug Delivery, Journal of Biomedical and Pharmaceutical Research 4 (1) 2015, 22-32.
  6. Bennett, D., Cabot, K., Foster, L., Lechuga-Ballesteros, D., & Tan, T. (1999). Liquid crystal forms of cyclosporin. US Patent Application 990352, WO 99/42124.
  7. Characterization of Liquid Crystals: A Literature Review. Jiang-Gen an, Saba Hina, Yong Yang, Min Xue and Yongsong Liu. s.l. Rev. Adv. mater. Sci. 2016; 44:398406.
  8. Chaudhary, H., Gautam, B., & Kumar, V. (2014). Lyotropic liquid crystals. (March).  http.//doi.org/10.403/09738398.134102.
  9. V. Viswanatha, C. Rajaramb, S. R. Fathimac, D. Bhanu Priyad, Brief Review of Liquid Crystals, International Journal of Trend in Scientific Research and Development (IJTSRD), 2018, Volume-2,956-961.
  10. Collings, P. J. & Hird, M. (1997). Introduction to Liquid Crystals. Bristol, PA: Taylor & Francis. ISBN 0-7484-0643-3.
  11. Structure of the Liquid-Crystal Phases of the Soap-water System: Middle Soap and Neat Soap. Luzzati V, Mustacchi H, Skoulios A. 4586, S. L. Bibcode. 1957; 180:600L. Doi: 10.1038/180600a0, 1957, Vol. 180.
  12. L. K. Omray, Liquid Crystals as Novel Vesicular Delivery System: A Review, Current trends in Technology and Science, Vol. II, Issue IV,347-349, 2013.
  13. Kamal Kumar Chaudhary, Pooja Kannojia , Nidhi Mishra, Liquid Crystal Systems in Drug Delivery, Research Gate, 2016, 217-243.
  14. Lancelot A, Sierra T, Serrano J L. Nanostructured liquid crystalline particles for drug delivery. Expert Opin Drug Deliv2014;11(4):547-64.
  15. Bunjes H, Rades T. Thermotropic liquid crystalline drugs. J Pharm Pharmacol, 57, 807-16, 2005.
  16. Silicone Liquid Crystals, Vesicles, and gels. Ferritto, Michael Salvatore, Lin, Zuchen a nd Jr, William James Schulz. s.l. Drug. Delivery Rev. 2001; 47:229-250. .
  17. Liquid-crystalline properties of aqueous suspensions of natural clay nanosheets. Paineau E. 110, S. L. Liquid Crystals Reviews, 2013, 1. doi:10.1080/21680396.2013.842130.
  18. Reinitzer, Friedrich (1888). "Beiträge zur Kenntniss des Cholesterins".Monatshefte für Chemie (Wien)9 (1): 421–441. doi:10.1007/BF01516710.
  19. Phase Behavior and Dynamics of the Liquid Crystal 4′butyl-4-(2-methylbutoxy) azoxybenzene. Juszy?skaGa??zka E. 21, s.l. The Journal of Physical Chemistry. 2014; 118:14982-14989.
  20. Sluckin, T. J.; Dunmur, D. A. & Stegemeyer, H. (2004). Crystals That Flow – classic papers from the history of liquid crystals. London: Taylor & Francis. ISBN 0-415-25789-1.
  21. Hirohisa Kawamoto (2013), The history of liquid crystal display and its industry, ELectro-technology Conference (HISTELCON), 2012 Third IEEE, ,DOI10.1109/HISTELCON.2012.64875 87.
  22. U. S. Patent 3,834,794: R. Soref, Liquid crystal electric field sensing measurement and display device, filed-June28, 1973.
  23. U. S. Patent 5,598,285: K. Kondo, H. Terao, H. Abe, M. Ohta, K. Suzuki, T. Sasaki, G. Kawachi, J. Ohwada, Liquid crystal display device filed Sept, 18, 1992 and Jan 20, 1993.
  24. Competing display technologies for the best image performance; A. J. S. M. de Vaan; Journal of the society of information displays, Volume 15, Issue 9 September 2007 Pages 657-666 h ttp://onlinelibrary.wiley.com/doi/10.1889/1.2785199.
  25. Castellano, Joseph A. (2005). Liquid Gold: The Story of Liquid Crystal Displays and the Creation of an Industry. World Scientific Publishing. ISBN 978-981-238-956-5.
  26. Ola Monika, Bhaskar Rajveer, Patil Gaurav R, Liquid Crystalline Drug Delivery System For Sustained Release Loaded With An Anti-tubercular Drug , Journal of Drug Delivery and Therapeutics,2018, 8(4):93-101.
  27. Omray L.K. Liquid crystals as novel vesicular delivery system: Review. Curr Trends Technol Sci, 2013; 2:347-353.
  28. [28]Dong-Hwan Kim, Alexander Jahn, SungJoon Cho, Jung Sun Kim, Min-Hyo Ki & Dae-Duk Kim, lyotropic liquid crystal system in drug delivery: a review ,Journal of pharmaceutical investigation,2015,45:1-11
  29. Makai M, Csanyi E, Dekany I, Nemeth Z, Eros I. Structural properties of non-ionic surfactant/glycerol/paraffin lyotropic crystals. Colloid Polym Sci, 281, 839-44, 2003.
  30. Chan HK, Gonda I. Methotrexate: Existence of different types of solid. Int J Pharm 6 8, 179-190, 1991.
  31. Bunjes H, Rades T. Thermotropic liquid crystalline drugs. J Pharm Pharmacol, 57, 807-16, 2005.
  32. Farkas E, Zelko R, Nemeth Z, Palinkas J, Marton S, Racz I. The effect of liquid crystalline structure on chlorhexidine diacetate release. Int J Pharm, 193, 239–45,  2000.
  33. Lara MG, Bentley MVLB, Collett JH. In vitro drug release mechanism and drug loading studies of cubic phase gels. Int J Pharm, 293, 241-250, 2005.
  34. Shah J C, Sadhle Y, Chilukuri DM. Cubic phase gels as drug delivery systems. Adv  Drug Deliv Rev, 47, 229-50, 2001.
  35. Shah MH, Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharm, 294, 161-171, 2005.
  36. Liquid Crystals Pharmaceutical Application: A Review. Dr. Sadhana Shahi, Vivek Ramteke, Iftequar Syed. International Journal of Pharmaceutical Research & Allied Sciences. 2012; 1(2):06-12
  37. Rego, J.A.; Harvey, Jamie A.A.; MacKinnon, Andrew L.; Gatdula, Elysse (January 2010). "Asymmetric synthesis of a highly soluble 'trimeric' analogue of the chiral nematic liquid crystal twist agent Merck S1011". Liquid Crystals37 (1): 37–43. doi:10.1080 /02678290903359291.
  38. Shaikh Zeba, Naik Nikita, Dusane Prachee, Rane Bhushan, Gujarathi Nayan, Ahirrao Rajesh. Liquid Crystalline System: A Novel Approach for Drug Delivery. Journal of Biomedical and Pharmaceutical Research. Vol. 4, Issue 1, 22-32, 2015.
  39. Phase Transitions of Liquid Crystal PAA in Confined Geometries. Shao Y, Zerda TW. 18, S.L. Journal of Physical Chemistry. 1998; 102:3387-3394.
  40. Kleinert H. and Maki K. (1981). Lattice Textures in Cholesteric Liquid Crystals". For tschritte der Physik29 (5): 219–259. Bibcode: 1981 ForPh..29. 219K. doi:10. 1002/prop.19810290503.
  41. Seideman, T (1990). The liquid-crystalline blue phases. Rep. Prog. Phys.53 (6): 659–705. Bibcode: 1990RPPh...53. 659S. doi:10.1088/0034-4885/53/ 6/ 001.
  42. Savita            Mandan,                Maitreyee              Chavan,  Cubosomes:          Future    of            Therapeutics, International journal of pharmacy and pharmaceutical research, March 2020 Vol.:17, Issue: 4, 60-69.
  43. Kawamoto H. The history of liquid crystal display. Proceedings of the IEEE, 460-99, 2002
  44. Acciacca A, Spong BR, Fleisher D, Hornedo NR. Mol. Pharmaceutics, 5: 956-967(2008).
  45. Rebecca J. Carlton, Jacob T. Hunter, Daniel S. Miller, Reza Abbasi, Peter C. Mushenheim, Lie Na Tan, and Nicholas L. Abbott, Chemical and biological sensing using liquid crystals, Liq Cryst Rev, 2013; 1(1): 29–51.
  46. L. Abbott. 1, s.l. US National Library of Medicine. 2013; 1:29-51.
  47. P. V. Patel, J. B. Patel, R. D. Dangar, K. S. Patel, K. N. Chauhan,“ Liquid Crystal Drug Delivery System”,Int. J. Of Pharma. &App. sci./1(1)/2010:118 123.
  48. Garry Myers, Kingsport, Tenn. “Drug delivery system utilizing liquid crystal structure” US 5,891,845/ April 6,1999.
  49. Paavola A, Kilpelaine I, YliruusiJ, Rosenberg P. Controlled release of vancomycine from poloxamer 407 gels. Int. J Pharm., 288:235-244(2005).
  50. Alexandre Lancelot, Teresa Sierra & Jose Luis Serrano, Nano-structured liquid-crystalline particles for drug delivery, informa healthcare, 2014, 547-564.
  51. Gan L, Wang J, Jiang M, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov Today 2013;18(5-6):290-7 .. An excellent overview on the possibilities of lipid-based nanocarriers for ophthalmic therapies, which are mainly, based on poorly water soluble drugs.
  52. Gan L, Han S, Shen J, et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: improving preocular retention and ocular bioavailability. Int J Pharm 2010; 396(1-2):179-87.
  53. Liquid crystals containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions. Gheorge Cioca, Lake Grove, James Hayward, Port jeffeson, Manuel
  54. L. Tan, Glen Clove, Morris Herstein scarsdae, N. Y. walter, Stamford, conn. s.l. US 4,999,348, March 12, 1991.
  55. R. K. Thapa, J. Y. Choi, B. K. Poudel, T. T. Hiep, S. Pathak, B. Gupta, H. Choi, C. S. Yong, J. O. Kim, ACS Appl. Mater. Interfaces 2015, 7, 20360 – 20368.
  56. M. Nasr, M. K. Ghorab, A. Abdelazem, Acta Pharm. Sin. B2015, 5, 79 – 88.
  57. S. Murgia, S. Bonacchi, A. M. Falchi, S. Lampis, V. Lippolis, V. Meli, M. Monduzzi, L. Prodi, J. Schmidt, Y. Talmon, et al.,Langmuir 2013, 29, 6673 – 6679.
  58. Imran Tadwee, Dr.Sadhana Shahi, Vivek Ramteke, Iftequar Syed, Liquid Crystals Pharmaceutical Application: A Review,IJPRAS, Volume 1, issue2 (2012), 06-11.
  59. Jean-Marie Lehn, Andreas Herrmann Nicolas Giuseppone “Imine Based Liquid Crystals for the Controlled Release of Bioactive Materials” Patent App. No 20090306196.
  60. Boyd BJ, Whittaker D V, Khoob S, DaveyG. Hexosome formed from glycerate surfactants-Formulation as a colloidal carrier for irinotecan.Internationa Journal of Pharmaceutics, 318: 154-162(2006).
  61. Zahra Karami and Mehrdad Hamidi, Cubosomes: remarkable drug delivery potential, Drug Discovery Today, Volume 5, Number 5, 790-799, May 2016.
  62. Rattanapak, T. et al. (2013) transcutaneous immunization using microneedles and cubosomes: mechanistic investigations using optical coherence tomography and two-photon microscopy. J. Control. Release 172, 894– 903.
  63. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations. Herai H, Gratieri T, Thomazine JA, Bentley MV, Lopez RFV. s. l. Int J Pharm. 2007; 329:88-93.
  64. Atyabi F, Khodaverdi E, Dinarvand R. Temperature modulated drug permeation through liquid crystal embedded cellulose membranes, International Journal of Pharmaceutics, 339:213-221(2007).
  65. Z. Liu, L. Luo, S. Zheng, Y. Niu, R. Bo, Y. Huang, J. Xing, Z. Li, D. Wang, Int. J. Nanomed. 2016, 11, 3571 – 3583.
  66. Farkas E, Kiss D, Zelk’o R. Study on the release of chlorhexidine base and salts from different liquid crystalline structures, International Journal of Pharmaceutics, 340:71-75(2007).
  67. Gheorge Cioca, Lake Grove, James Hayward, Port jeffeson, Manuel L. Tan, Glen Clove, Morris Herstein Scarsdae, N. Y. Walter, Stamford, Conn “Liquid crystals containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions” US 4,999,348 March 12, 1991.
  68. Ryo Akamastsu, Masahiro Fujii, Tomoki Sakaguchi, Eijiro Horisawa Japan“Liquid crystals emulsion type pharmaceutical composition containing cyclosporine and therapeutic method of treating cutaneous disease therewith” US 2010/190695 A1/ July 29,2010.
  69. Garry Myers, Kingsport, Tenn. “Drug delivery system utilizing liquid crystal structure” US 5,891,845/ April 6,1999
  70. https://scholar.google.co.in/scholarq=%5B68%5D+Garry+Myers,+Kingsport,+Tenn.+%E2%80%9CDrug+delivery+system+utilizing+liquid+crystal&hl=en

                            &as_sdt=0&as_vis=1&oi=scholart